RBC global strategists are optimistic about the market's performance in 2024, favoring sectors like Financials, Materials, Health Care, Energy, and ...
Teva completes enrollment for Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia. Results expected in 2024. #schizophrenia #clinicaltrials